

23 July 2024

ASX Announcement

FY24 Trading Result (unaudited)

FY24 Financial Highlights

PolyNovo Limited (PolyNovo or Company) is pleased to provide indicative trading results for FY24.

- Total revenue including BARDA of **A\$104.8m up 57.5%** on STLY of **A\$66.5m**.
- FY24 sales of **A\$92.0m up 54.5%** on STLY of **A\$59.6m**.
- Strong growth in U.S. sales of **A\$68.7m up 49.0%** on STLY of **A\$46.1m**.
- ROW sales of **A\$23.3m up by 73.1%** on STLY of **A\$13.5m** including strong performances in developed markets like UKI, Germany and ANZ.
- Surgeon education and charitable contributions, widely used to support patients in conflict zones.

The Company will disclose the audited FY24 results on 23 August 2024.

Chairman, David Williams said: *“There are many highlights in the year just past. One is the amount of organic growth. A second is the strength of the UKI market from a slow start in non-burns. A third is the enormous need for our product in conflict zones and developing countries supported by WHO, Charities and governments.”*

CEO, Swami Raote said: *“Thanks to the efforts of our clinicians and our people, we continue to make significant strides in our mission to **redefine healing** for our patients. We are proud of reaching a milestone of touching and healing over 50,000+ patients across 41 countries in our relatively short commercial history. We are making a meaningful difference to patient outcomes, as we help reduce cost and complexity across different healthcare systems, further accelerating NovoSorb adoption. Our clinicians continue to provide superior insights to help us take NovoSorb technology across different clinical indications through our expanding product portfolio. Although I am proud of what our people have achieved, I remain acutely conscious of our responsibility to meet a global need to heal millions more.”*

This announcement has been authorised by PolyNovo General Counsel & Company Secretary, Lior Harel.

About PolyNovo®

PolyNovo is a disruptive ASX 200 medical technology company, based out of Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 50,000+ patients across 41 countries, the company is investing for growth via new products, indications, and markets with a view to treat millions more. For more information see polynovo.com

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.